The Canadian Association of Gastroenterology Interactive Lecture Series: A virtual learning tool for the office and home

En français voir page 733

Richard N Fedorak MD¹, Desmond J Leddin MB²

¹Chair, CAG Lecture Series, ²Chair, CAG Education Committee

WHAT IS THE CANADIAN ASSOCIATION OF GASTROENTEROLOGY (CAG) INTERACTIVE LECTURE SERIES?

The CAG Interactive Lecture Series is celebrating its first anniversary this month, and is cosponsored by the CAG, Abbott Laboratories Ltd, Axcan Pharma Inc and Schering Canada Inc.

This online, CAG-directed, educational program is a highly innovative 'virtual' learning opportunity that allows you to visually review lectures, workshops and symposia sessions from the Canadian Digestive Diseases Week and other national and provincial educational events at your leisure.

The state-of-the-art lectures, symposia and workshops available on the CAG Interactive Lecture Series are chosen by the CAG to represent the broad spectrum of gastrointestinal clinical practice and to appeal to gastroenterologists, surgeons and general internists with a major interest in gastrointestinal disorders.

Educational presentations that occur across the country and throughout the year are constantly and carefully evaluated, and with the author's permission, digitally taped and remastered into an outstanding visual and audio presentation. You are able to listen to and watch these educational presentations wherever and whenever you like. Neither the content nor the context of the presentation is ever altered.

HOW DO I ACCESS THE CAG INTERACTIVE LECTURE SERIES?

The CAG would like to remind you that the subscription to the CAG Interactive Lecture Series is free!

To subscribe to the CAG Interactive Lecture Series you must obtain an introduction CD-ROM. This CD-ROM acts like a key and permits you to access each of the educational presentations as they become available online, which occurs on a weekly basis. The CD-ROM also permits you to download new presentations as they become available and acts as a storage facility for accumulating lectures for future or repeat viewing.

The CD-ROM is available by e-mailing your request to <contact@cdpharma.com> or by contacting your local representative from one of the cosponsors: Abbott Laboratories Ltd, Montreal; Axcan Pharma Inc, Mont St-Hilaire; and Schering Canada Inc, Pointe-Claire.

Please be sure to check the CAG Web site at <<http://www.cag-acg.org/sponsors/education.htm>> for a complete list of all available presentations and regularly for any new online presentations that may have been added to the program. There are now more than 30 h worth of world-class presentations from over 90 separate lectures available through this exciting program and more are being added weekly (Table 1).

WHAT DO I GAIN FROM THE CAG INTERACTIVE LECTURE SERIES?

The CAG Interactive Lecture Series is ideal for the busy practitioner who cannot always attend a live educational event. The CAG selects presentations that occur at a multitude of venues across Canada, making it easy for the physician to feel comfortable that he/she is not missing important information. Presentations selected must be particularly relevant and timely in the area of management or therapeutics of gastrointestinal disorders.

The CAG is proud to acknowledge its Benefactor Corporate Sponsors:

Abbott Laboratories Ltd.

AstraZeneca Canada Inc.

Axcan Pharma Inc.

Janssen-Ortho Inc.

Accessing the presentations on your own time and leisure, and using them to answer questions generated in your day-to-day practice permits the CAG Interactive Lecture Series to be used to meet the Royal College of Physicians and Surgeons of Canada's requirements for Section 4 credits (1credit/h, no maximum).

You can use the CAG Interactive Lecture Series as a resource to obtain the latest information and updates on a particular area. For example, you may wish for an update

on the latest developments in the use of antiviral therapy for viral hepatitis, immunomodulators for irritable bowel disease (IBD) or acid suppressors for dyspepsia. By scanning the presentations available on the CAG Interactive Lecture Series you will find the latest updates by world-renowned experts in the field.

We encourage you to join the growing number of physicians who are using the CAG Interactive Lecture Series as an important tool in their daily learning and clinical practice.

TABLE 1
Presentations available through the Canadian Association of Gastroenterology (CAG) Interactive Lecture Series

Presentation number	CAG Interactive Lecture Series presentation title	Presenter
1	Existing Evidence on the Safety of Long Term PPI VIIth World Congress of the International Society for Diseases of the Esophagus	Dr Richard Hunt
2	Should PPI Be Used Chronically or on Demand? VIIth World Congress of the International Society for Diseases of the Esophagus	Dr Naoki Chiba
3	Inducing Remission in Ulcerative Colitis Trends in Inflammatory Bowel Disease Therapy 1999 – An Official Satellite Symposium of GASTRO'99	Dr Stephen B Hanauer
4	Remission Maintenance in Ulcerative Colitis Trends in Inflammatory Bowel Disease Therapy 1999 – An Official Satellite Symposium of GASTRO'99	Dr Jurgen Schölmerich
5	Induction Therapy in Crohn's Disease Trends in Inflammatory Bowel Disease Therapy 1999 – An Official Satellite Symposium of GASTRO'99	Dr A Hillary Steinhart
6	Maintenance of Remission in Crohn's Disease: Efficacy of Drug Therapy Trends in Inflammatory Bowel Disease Therapy 1999 – An Official Satellite Symposium of GASTRO'99	Dr Paul Rutgeerts
7	Medical Management of Proctosigmoiditis and Hemorrhoids Trends in Inflammatory Bowel Disease Therapy 1999 – An Official Satellite Symposium of GASTRO '99	Prof Massimo Campieri
8	Myths and Facts in the Role of Endoscopy, pH Monitoring and Other Forms of Investigation in GERD Canadian Digestive Diseases Week – Highlights From the 5th Annual Meeting	Dr André Duranceau
9	Myths and Facts in the Management of Patients With No Endoscopy, or With Negative Endoscopy or With Mild Esophagitis Canadian Digestive Diseases Week – Highlights From the 5th Annual Meeting	Dr Richard PE Reynolds
10	Myths and Facts in the Principles of Long-Term Treatment of Patients With Severe Esophagitis Canadian Digestive Diseases Week – Highlights From the 5th Annual Meeting	Dr Wilfred M Weinstein
11	Beneficial Effect of <i>H pylori</i> Eradication Therapy on Long-Term Symptom Relief in Primary Care Patients With Uninvestigated Dyspepsia: The CADET-Hp Study Canadian Digestive Diseases Week – Highlights From the 5th Annual Meeting	Dr Naoki Chiba
12	Barrett's, <i>H pylori</i> and GE Junction Cancer Canadian Digestive Diseases Week – Highlights From the 5th Annual Meeting	Dr Wilfred M Weinstein
13	The Esophagus: In Sickness and in Health Canadian Digestive Diseases Week – Highlights From the 5th Annual Meeting	Dr William Paterson

continued on next page

TABLE 1 (continued)
Presentations available through the Canadian Association of Gastroenterology (CAG) Interactive Lecture Series

Presentation number	CAG Interactive Lecture Series presentation title	Presenter
14	Pathogenesis and Prevention of Colon Cancer	Dr Raymond DuBois
	Canadian Digestive Diseases Week – Highlights From the 5th Annual Meeting	
15	From the Farm to Big Pharma: The Development of Hepatitis B Antiviral Therapy	Dr Lorne Tyrrell
	Canadian Digestive Diseases Week – Highlights From the 5th Annual Meeting	
16	RCPSC Maintenance of Certification	Dr John WD McDonald
	Canadian Digestive Diseases Week – Highlights From the 5th Annual Meeting	
17	The Efficacy of Biological Therapy in IBD	Dr Stephan Targan
	Canadian Digestive Diseases Week – Highlights From the 5th Annual Meeting	
18	New Approaches to Steroid Dependent & Refractory Crohn's Disease	Dr Gary Lichtenstein
	New Paradigms in the Management of Crohn's Disease	
19	Current Management Strategies for Fistulous Crohn's Disease	Dr Remo Panaccione
	New Paradigms in the Management of Crohn's Disease	
20	Efficacy & Safety of Biologics	Dr Sander van Deventer
	New Paradigms in the Management of Crohn's Disease	
21	Cytokines in Inflammatory Bowel Disease: Role in Pathophysiology, Diagnostics and Therapy	Dr Stefan Schreiber
	ULIBD 2001: Update on Liver & Inflammatory Bowel Diseases	
22	Genomics and Proteomics	Dr Jack R Wands
	ULIBD 2001: Update on Liver & Inflammatory Bowel Diseases	
23	Pathogenesis of Chronic Inflammation	Dr Valeer J Desmet
	ULIBD 2001: Update on Liver & Inflammatory Bowel Diseases	
24	Use of PPI Acid Suppression as a Diagnostic Test in the Management of GERD and Dyspepsia	Dr Raymond Lahaie
	Canadian Digestive Diseases Week: Highlights from the 6th Annual Meeting	
25	Top 4 Basic Science Abstracts From Presidential Plenary/Poster Sessions	Dr D Grant Gall
	10th Annual Digestive Disease Week Review Course	
26	Clinical Abstracts: Presidential Plenary Sessions	Dr Robert Hilsden
	10th Annual Digestive Disease Week Review Course	
27	Cancer and Cancer Screening	Dr Ron Bridges
	10th Annual Digestive Disease Week Review Course	
28	Hepatobiliary/Non-Viral (Including ASLD)	Dr Vince G Bain
	10th Annual Digestive Disease Week Review Course	
29	Hepatobiliary/Viral (Including ASLD)	Dr Mark G Swain
	10th Annual Digestive Disease Week Review Course	
30	Advanced Therapeutic Endoscopy	Dr Gary R May
	10th Annual Digestive Disease Week Review Course	
31	Extra-Esophageal Manifestations of GERD	Dr Connie M Switzer
	10th Annual Digestive Disease Week Review Course	
32	Ulcerative Colitis	Dr Bruce Yacyshyn
	10th Annual Digestive Disease Week Review Course	
33	Crohn's Disease	Dr Remo Panaccione
	10th Annual Digestive Disease Week Review Course	
34	Gastroesophageal Reflux Disease	Dr Philip Blustein

continued on next page

TABLE 1 (continued)**Presentations available through the Canadian Association of Gastroenterology (CAG) Interactive Lecture Series**

Presentation number	CAG Interactive Lecture Series presentation title	Presenter
35	Drug-Drug Interactions: The Role of the Cytochrome P-450 Enzyme System in the Metabolism of Proton Pump Inhibitors	Dr Victor Plourde
36	Drug-Drug Interactions With Proton Pump Inhibitors: The Role of the Cytochrome P-450 Enzyme System in the Metabolism of Proton Pump Inhibitors	Dr John R Horn
37	MRCP vs ERCP CDDW 2002: Imaging and Endoscopy	Dr Joseph Romagnuolo
38	CT-Colography (Virtual Colonoscopy) vs Colonoscopy CDDW 2002: Imaging and Endoscopy	Dr Benoit C Pineau
39	Peptic Ulcer Bleeding CDDW 2002: Imaging and Endoscopy	Dr Norman Marcon
40	Pharmacological Advances in the Treatment of Upper Gastrointestinal Bleeding CDDW 2002: Imaging and Endoscopy	Dr Alan N Barkun
41	Advances in Noncardiac Chest Pain Canadian Digestive Diseases Week 2002	Dr William Paterson
42	Recent Studies on Esophageal Surgery Canadian Digestive Diseases Week 2002	Dr André Duranceau
43	Extraesophageal Presentations of GERD Canadian Digestive Diseases Week 2002	Dr Michel Boivin
44	Introduction to Ambulatory Care in Canada Canadian Digestive Diseases Week 2002	Dr Flavio M Habal
45	Politics of Independent Ambulatory Endoscopy – Regulatory Bodies: Where Is the Hold Up? Independent Ambulatory Endoscopy in Canada: Is the Time Ripe?	Dr Michael I Gould
46	The Cost/Economics of Setting Up an Outpatient Endoscopy Clinic Independent Ambulatory Endoscopy in Canada: Is the Time Ripe?	Don Montgomery
47	Personal Experience in Running an Outpatient Ambulatory Care Endoscopy Unit – Is it Worth It? Independent Ambulatory Endoscopy in Canada: Is the Time Ripe?	Dr Murray Fisher
48	Management of GI Bleeding	Dr Daniel C Sadowski
49	Bone Loss and IBD ULIBD 2001: Update on Liver & Inflammatory Bowel Diseases	Dr Gordon R Greenberg
50	Emerging Indications for Infliximab ULIBD 2001: Update on Liver & Inflammatory Bowel Diseases	Dr Elena Hitraya
51	Malignancy-Lymphoma in CD ULIBD 2001: Update on Liver & Inflammatory Bowel Diseases	Dr Roger B Cohen
52	The Role of Infliximab in the Treatment of CD: US Experience ULIBD 2001: Update on Liver & Inflammatory Bowel Diseases	Dr Stephen Hanauer
53	Health Care Burden From HCV in North America: Projections for the Future ULIBD 2001: Update on Liver & Inflammatory Bowel Diseases	Dr Gary L Davis
54	The Effect of Antiviral Therapy on Hepatic Fibrosis in Chronic Hepatitis C ULIBD 2001: Update on Liver & Inflammatory Bowel Diseases	Dr Thierry Poynard
55	Future Therapies in HCV ULIBD 2001: Update on Liver & Inflammatory Bowel Diseases	Dr Willis C Maddrey
56	Fibre and Colon Cancer Canadian Digestive Diseases Week – Highlights from the 6th Annual Meeting	Dr Young-In Kim

continued on next page

TABLE 1 (continued)
Presentations available through the Canadian Association of Gastroenterology (CAG) Interactive Lecture Series

Presentation number	CAG Interactive Lecture Series presentation title	Presenter
57	Long-Term Complications of TPN Canadian Digestive Diseases Week – Highlights from the 6th Annual Meeting	Dr J Scott Whittaker
58	Short Bowel Syndrome: Role of Trophic Factors in Intestinal Adaptation Canadian Digestive Diseases Week – Highlights from the 6th Annual Meeting	Dr James S Scolapio
59	Recent Advances in the Treatment of Hepatitis C Canadian Digestive Diseases Week – Highlights from the 6th Annual Meeting	Dr Jay H Hoofnagle
60	Diagnosis and Management of IBS: Meta-Analysis of IBS Pharmacotherapy Canadian Digestive Diseases Week – Highlights from the 6th Annual Meeting	Dr John K Marshall
61	Functional GI Disorders: Points of View Canadian Digestive Diseases Week – Highlights from the 6th Annual Meeting	Dr W Grant Thompson
62	The Gut Response to Stress: Implications for Functional GI Disorders Canadian Digestive Diseases Week – Highlights from the 6th Annual Meeting	Dr Victor Plourde
63	Should I Try to Convince my Hospital to Buy EUS? Canadian Digestive Diseases Week – Highlights from the 6th Annual Meeting	Dr Anand Sahai
64	Metal or Plastic Stents for Bile Duct Obstruction: What Is the Most Cost-Effective Approach? Canadian Digestive Diseases Week – Highlights from the 6th Annual Meeting	Dr Alan Barkun
65	Utility of Serological Immune Markers in the Diagnosis, Differentiation and Stratification of IBD Canadian Digestive Diseases Week – Highlights From the 6th Annual Meeting	Dr Marla Dubinsky
66	Purine Metabolites in IBD: Therapeutic Use and Metabolic Testing Canadian Digestive Diseases Week – Highlights From the 6th Annual Meeting	Dr William Sandborn
67	Treating Fistulizing Crohn's Disease Canadian Digestive Diseases Week – Highlights From the 6th Annual Meeting	Dr Brian G Feagan
68	Probiotic and Antibiotic Therapy for IBD Canadian Digestive Diseases Week – Highlights From the 6th Annual Meeting	Dr Fergus Shanahan
69	Special Pediatric Management Issues in IBD Canadian Digestive Diseases Week – Highlights From the 6th Annual Meeting	Dr Ernest Seidman
70	The Role of 5-ASA and Corticosteroids in Treating Crohn's Disease 2001: A GI and Liver Odyssey Program	Dr A Hillary Steinhart
71	Future Treatments in IBD: Where Do We Go From Here? 2001: A GI and Liver Odyssey Program	Dr Kenneth Croitoru
72	Cirrhose biliaire primitive et hypertension portale : la place de l'ursodiol	Dr Pierre-Michel Huet
73	Nonalcoholic Steatohepatitis: An Expanding Clinical Entity	Dr David Brandhagen
74	Update on the Treatment of NASH	Dr Keith Lindor
75	Osteoporosis in IBD	Dr Kerry Siminoski
76	Therapy With AZA/6-MP: The Role of Metabolite Monitoring and TPMT Pharmacogenetics	Dr Ernest Seidman
77	Maintenance Therapy in Inflammatory Bowel Disease: Focus on Mesalamine	Dr Malcolm Champion
78	The Truth About Probiotics in Inflammatory Bowel Disease	Dr Richard Fedorak
79	So How Does UDCA Play a Role in the Treatment of Cholestasis? CDDW 2002: From Transporters to Viruses – New Mechanisms and Treatment for Cholestasis	Dr Ulrich Beuers
80	PBC and PSC: Infectious Diseases? CDDW 2002: From Transporters to Viruses – New Mechanisms and Treatment for Cholestasis	Dr James M Neuberger

continued on next page

TABLE 1 (continued)
Presentations available through the Canadian Association of Gastroenterology (CAG) Interactive Lecture Series

Presentation number	CAG Interactive Lecture Series presentation title	Presenter
81	What Governs Normal Bile Flow? CDDW 2002: From Transporters to Viruses – New Mechanisms and Treatment for Cholestasis	Dr Alan Hofmann
82	Genetic Mutations Causing Cholestasis in Children and Adults CDDW 2002: From Transporters to Viruses – New Mechanisms and Treatment for Cholestasis	Dr Rick Schreiber
83	Current Therapy for Chronic Hepatitis C Hepatology Update 2002	Dr S Victor Feinman
84	Treatment of Chronic Hepatitis B Hepatology Update 2002	Dr Morris Sherman
85	Endoscopy and Biopsy Issues: Why, When, Where? Diagnostic and Therapeutic Approaches in GI and Liver Disease	Dr Wilfred M Weinstein
86	Diagnosis of Suspected Small Bowel Bleeding Diagnostic and Therapeutic Approaches in GI and Liver Disease	Dr Dennis Jensen
87	Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease Update on Liver and Inflammatory Bowel Diseases 2002	Dr Remo Panaccione
88	A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-Term Treatment Regimen (ACCENT 1) Update on Liver and Inflammatory Bowel Diseases 2002	Dr Richard Fedorak
89	Clinical Trials With Infliximab: Implications for Practice Update on Liver and Inflammatory Bowel Diseases 2002	Dr Stephen Hanauer
90	Optimizing Long-Term Treatment Algorithms in Crohn's Disease Disease Modification in IBD: Exploring Current Clinical Opportunities – Symposium	Dr Stephen B Hanauer
91	Debate: Infliximab Is a Preferable Treatment to Corticosteroids for Induction of Remission in Patients With Active Crohn's Disease – PRO Update on Liver and Inflammatory Bowel Diseases 2002	Dr Daniel H Present
92	Debate: Infliximab Is a Preferable Treatment to Corticosteroids for Induction of Remission in Patients With Active Crohn's Disease – CON Update on Liver and Inflammatory Bowel Diseases 2002	Dr William J Sandborn
93	Are Glucocorticosteroids Obsolete in IBD?	Dr Paul J Rutgeerts
94	Disease Modification in IBD: Improving Treatment Outcomes Disease Modification in IBD: Exploring Current Clinical Opportunities – Symposium	Dr Paul J Rutgeerts
95	Fistulizing Crohn's Disease: Evolving Clinical Expectations Disease Modification in IBD: Exploring Current Clinical Opportunities – Symposium	Dr Bruce E Sands

ASA Acetylsalicylic acid; AZA/6-MP Azathioprine/6-Mercaptopurine; CD Crohn's disease; CT Computed tomography; ERCP Endoscopic retrograde cholangiopancreatography; EUS Endoscopic ultrasound; GE Gastroesophageal; GERD Gastroesophageal reflux disease; GI Gastrointestinal; HCV Hepatitis C virus; IBD Inflammatory bowel disease; IBS Irritable bowel syndrome; MRCP Magnetic resonance cholangiopancreatography; NASH Nonalcoholic steatohepatitis; PBC Primary biliary cirrhosis; PPI Proton pump inhibitors; PSC Primary sclerosing cholangitis; TPMT Thiopurine methyltransferase; TPN Total parenteral nutrition; UDCA Ursodeoxycholic acid; ULIBD Update on liver and inflammatory bowel diseases; US United States